These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24338045)

  • 1. Author's reply to Borg et al. Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars".
    Calvo B
    Drug Saf; 2014 Feb; 37(2):125-6. PubMed ID: 24338045
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars".
    Borg JJ; Serracino-Inglott A; Azzopardi LM; Schneider CK
    Drug Saf; 2014 Feb; 37(2):123-4. PubMed ID: 24338043
    [No Abstract]   [Full Text] [Related]  

  • 3. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
    Sugay J
    Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval Process: An Overview of Biosimilars in the Oncology Setting.
    Sowinski-Raff L
    Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic product identification and US pharmacovigilance in the biosimilars era.
    Felix T; Johansson TT; Colliatie JA; Goldberg MR; Fox AR
    Nat Biotechnol; 2014 Feb; 32(2):128-30. PubMed ID: 24509751
    [No Abstract]   [Full Text] [Related]  

  • 10. The Regulation of Biosimilars in Latin America.
    Garcia R; Araujo DV
    Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view.
    Pineda C; Caballero-Uribe CV; de Oliveira MG; Lipszyc PS; Lopez JJ; Mataos Moreira MM; Azevedo VF
    Clin Rheumatol; 2015 Apr; 34(4):635-40. PubMed ID: 25673060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective.
    Sharma A; Kumar N; Kuppermann BD; Bandello F; Loewenstein A
    Br J Ophthalmol; 2020 Jan; 104(1):2-7. PubMed ID: 31315829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iraqi regulatory authority current system and experience with biosimilars.
    Al-Kinani KK; Ibrahim MJ; Al-Zubaidi RF; Younus MM; Ramadhan SH; Kadhim HJ; Challand R
    Regul Toxicol Pharmacol; 2020 Nov; 117():104768. PubMed ID: 32861742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory challenges with biosimilars: an update from 20 countries.
    Kang HN; Thorpe R; Knezevic I; Casas Levano M; Chilufya MB; Chirachanakul P; Chua HM; Dalili D; Foo F; Gao K; Habahbeh S; Hamel H; Kim GH; Perez Rodriguez V; Putri DE; Rodgers J; Savkina M; Semeniuk O; Srivastava S; Tavares Neto J; Wadhwa M; Yamaguchi T
    Ann N Y Acad Sci; 2021 May; 1491(1):42-59. PubMed ID: 33222245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
    Qian J; Truong CB; Tanni KA
    BioDrugs; 2021 May; 35(3):375-377. PubMed ID: 33860920
    [No Abstract]   [Full Text] [Related]  

  • 19. Biosimilars: A new scenario in biologic therapies.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Reumatol Clin; 2017; 13(5):287-293. PubMed ID: 27372258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
    Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
    Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.